Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review

Journals Menu

Follow SCIRP

ISSN Print: 2164-3121
ISSN Online: 2164-313X
www.scirp.org/journal/ojmc
E-mail: ojmc@scirp.org

"Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review"
written by Lou Anna Voli, Janat A. Mamyrbékova, Jean-Pierre Bazureau,
published by Open Journal of Medicinal Chemistry, Vol.10 No.3, 2020

has been cited by the following article(s):

[1]	Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
	Pharmaceuticals, 2023

[2]	Molecular perspective on targeted therapy in breast cancer: a review of current status
	Medical Oncology, 2022

[3]	Introductory chapter: Protein kinases as promising targets for drug design against cancer
	Protein kinases promising targets for …, 2021

[1]	A review of FDA approved drugs and their formulations for the treatment of breast cancer Frontiers in Pharmacology, 2023 DOI:10.3389/fphar.2023.1184472

[2]	Molecular perspective on targeted therapy in breast cancer: a review of current status Medical Oncology, 2022 DOI:10.1007/s12032-022-01749-1

[3]	Protein Kinases - Promising Targets for Anticancer Drug Research Biochemistry, 2021 DOI:10.5772/intechopen.100315

Follow SCIRP